Sales ended at MNOK 133.8, 3.5% above first quarter last year (MNOK 129.3). Currency neutral sales of own products was down 1%. Recurring sales remain high at 75% or MNOK 83.5 (68% or MNOK 73.8) for the quarter. Strong quarter for the direct sales operations inEurope and EMEA delivers 32% currency neutral growth while growth inAMERICAS and APAC was influenced by strong comparables from Q1 last year. Operating profit (EBIT) for the quarter ended at MNOK 32.1 giving a 24.0% EBIT margin (MNOK 33.5, a 25.9% margin).Medistim's third-party distribution business signed a contract with the cardiovascular companyPeters Surgical , to distribute their products inSweden andNorway . Solid cash position at quarter end with MNOK 170.3 and no long-term interest-bearing debt.The General Assembly decided a dividend ofNOK 4.50 (NOK 4.50 ) per share, a total of MNOK 82.4.
Click here for more information
© Oslo Bors ASA, source